Safety of ciprofloxacin. A review

Scand J Infect Dis Suppl. 1989:60:120-8.


In clinical trials phase II and III world wide 8,861 courses of ciprofloxacin were entered into the data base for safety evaluation. The following adverse reactions were observed-gastrointestinal 5%, metabolic and nutritional 4.6%, central nervous system 1.6%, skin 1.4%, hemic and lymphatic 1%, cardiovascular 0.4%, body as a whole 0.4%, urogenital 0.3%, special senses 0.3%, musculo-skeletal 0.1%, respiratory 0.08%. Total incidence of adverse reactions was 10.2%. Ciprofloxacin interacts with theophylline and certain antacids. Caution should be exercised in treating patients with known history of convulsions. Crystalluria does not appear to be a problem. Ciprofloxacin is well tolerated and side effects are usually mild or moderate in intensity. However, unusual and unexpected reactions have to be watched for.

Publication types

  • Clinical Trial
  • Comparative Study
  • Review

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Animals
  • Child
  • Ciprofloxacin / adverse effects*
  • Ciprofloxacin / pharmacology
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Drug Evaluation
  • Drug Interactions
  • Humans


  • Ciprofloxacin